- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Review, Journal: COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus. (Pubmed Central) - Jan 13, 2022 World Health Organization guidelines on preventive measures and use of soaps, alcohol-based hand-rubs and wearing face masks have also been described. The vaccines that are in one of the phases of human trials, namely Oxford University's vaccine, the United States-based Moderna's vaccine, India's Covaxin and the Russian vaccine, have also been incorporated in the review article.
- |||||||||| ivermectin oral / Generic mfg.
Clinical, Clinical protocol, Retrospective data, Review, Journal: Strongyloides stercoralis in Swiss dogs - a retrospective study suggests an increasing occurrence of this potentially zoonotic parasite as a consequence of dog imports. (Pubmed Central) - Jan 12, 2022 Ivermectin off-label protocols described in the literature, e.g. 0,8 mg/kg BW s.c. or 0,5 mg/kg BW i.m. repeated after 2 weeks, were successful based on control examinations performed 3-10 weeks later. Strongyloides stercoralis infections are clinically relevant, potentially zoonotic and need to be included in differential diagnoses in case of canine gastrointestinal and respiratory disorders, especially in young and imported dogs.
- |||||||||| ivermectin oral / Generic mfg.
Review, Journal: A narrative review of the roles of topical permethrin and oral ivermectin in the management of infantile scabies. (Pubmed Central) - Jan 11, 2022 Ivermectin use is recommended when authorised topical treatment has failed, in crusted scabies, in cases where compliance with topical agents may be problematic, and in infants with severely inflamed or broken skin where prescription of topical therapies would likely cause cutaneous and systemic toxicity. Additional high-quality studies are needed to guide best practice in the management of infantile scabies.
- |||||||||| ivermectin long-acting injectable / Monash University, The Peter Doherty Institute for Infection and Immunity
Review, Journal: Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. (Pubmed Central) - Jan 11, 2022 Thereafter, we discuss IVM's mechanism and highlight the clinical advantages that could potentially contribute towards disabling the viral replication of SARS-CoV-2. In summary, the collective review of recent efforts suggests that IVM has a prophylactic effect and would be a strong candidate for clinical trials to treat SARS-CoV-2.
- |||||||||| ivermectin oral / Generic mfg.
Clinical, Review, Journal: A clinical review and history of pubic lice. (Pubmed Central) - Jan 8, 2022 In true resistance, a different pediculicide class should be used e.g., second-line agents: phenothrin, malathion or ivermectin. Lice have existed long before humans and given their adaptability, despite habitat challenges from fashion trends in body hair-removal, are likely to continue to survive.
- |||||||||| hydroxychloroquine / Generic mfg.
Review, Journal: Formulating Hypotheses for Different Study Designs. (Pubmed Central) - Jan 8, 2022 A hypothesis should be tested by ethically sound experiments with meaningful ethical and clinical implications. The coronavirus disease 2019 pandemic has brought into sharp focus numerous hypotheses, some of which were proven (e.g. effectiveness of corticosteroids in those with hypoxia) while others were disproven (e.g. ineffectiveness of hydroxychloroquine and ivermectin).
- |||||||||| ivermectin oral / Generic mfg.
Journal: SIT1 transporter as a potential novel target in treatment of COVID-19. (Pubmed Central) - Jan 7, 2022 Thus, further clinical trials are warranted to confirm the potential favorable effects of targeting the SIT1 transporter and glycine levels in the treatment of COVID-19, particularly for the severe case of disease associated with hyperglycemia, inflammation, and T2D. These findings suggest that SIT1 may potentially represent one of the missing pieces in the complex puzzle observed between these two pandemic diseases and the potential novel target for their efficient treatment.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Small-molecule antiviral agents in ongoing clinical trials for COVID-19. (Pubmed Central) - Jan 6, 2022 These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed.
|